Second Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis : A Single-Center Prospective Experience
Copyright © 2023 Elsevier Inc. All rights reserved..
Immunosuppressive therapy is useful in persons with multiple sclerosis (MS), and autologous hematopoietic stem cell transplantation (aHSCT) is the most effective immunosuppressive treatment in this setting. Information on the usefulness of a second aHSCT in patients with MS is scarce. In a group of 1225 individuals with MS prospectively managed with aHSCT, we analyzed the salient features of 4 patients who received 2 consecutive transplants. After a moderate initial response to the first aHSCT, the patients were transplanted again after deterioration of their neurologic status; the second transplant was well tolerated and, in all instances, was completed on an outpatient basis and with no associated undesired toxicity. The autograft protocol is registered in ClinicalTrials.gov, identifier NCT02674217. After the second graft, the expanded disability status scale score stabilized in 2 patients; in 1, the post-transplant period was too short to assess the response, and in another, the development of associated Parkinson's disease precluded the assessment of the outcome. In conclusion, a second aHSCT in persons with MS is feasible, safe, and may lead to a positive response in some cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Transplantation proceedings - 56(2024), 1 vom: 03. Jan., Seite 211-214 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hernández-Flores, Edgar J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT02674217 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transproceed.2023.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366676601 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366676601 | ||
| 003 | DE-627 | ||
| 005 | 20240220232225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transproceed.2023.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM366676601 | ||
| 035 | |a (NLM)38177042 | ||
| 035 | |a (PII)S0041-1345(23)00790-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hernández-Flores, Edgar J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Second Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis |b A Single-Center Prospective Experience |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02674217 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Immunosuppressive therapy is useful in persons with multiple sclerosis (MS), and autologous hematopoietic stem cell transplantation (aHSCT) is the most effective immunosuppressive treatment in this setting. Information on the usefulness of a second aHSCT in patients with MS is scarce. In a group of 1225 individuals with MS prospectively managed with aHSCT, we analyzed the salient features of 4 patients who received 2 consecutive transplants. After a moderate initial response to the first aHSCT, the patients were transplanted again after deterioration of their neurologic status; the second transplant was well tolerated and, in all instances, was completed on an outpatient basis and with no associated undesired toxicity. The autograft protocol is registered in ClinicalTrials.gov, identifier NCT02674217. After the second graft, the expanded disability status scale score stabilized in 2 patients; in 1, the post-transplant period was too short to assess the response, and in another, the development of associated Parkinson's disease precluded the assessment of the outcome. In conclusion, a second aHSCT in persons with MS is feasible, safe, and may lead to a positive response in some cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Gallardo-Pérez, Moisés Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Robles-Nasta, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Montes-Robles, Merittzel Abigail |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Bonilla, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pastelín-Martínez, María De Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Ocaña-Ramm, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Olivares-Gazca, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Delgado, Guillermo J |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Argüelles, Guillermo J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation proceedings |d 1969 |g 56(2024), 1 vom: 03. Jan., Seite 211-214 |w (DE-627)NLM000011029 |x 1873-2623 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:1 |g day:03 |g month:01 |g pages:211-214 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transproceed.2023.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 1 |b 03 |c 01 |h 211-214 | ||